German Health Ministry to invest €6.2bn in vaccines
The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1999 entries already.
Entries by Thomas Gabrielczyk
V-Bio Ventures launches second fund at €78m
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise €35m in Series A extension
Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.
German antibodies in demand in USA
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Omnix Medical bags €10.8m from EIC Accerator Fund
Israel’s Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany orders antibody therapies from USA
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
Servier and MiNA Therapeutics sign €220m deal
French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.